EMA Suspends Leo’s Actinic Keratosis Drug Picato
Also Limits Use Of High-Strength Estradiol Creams
Executive Summary
The latest drug safety actions by the European Medicines Agency affect products for dermatological use and vaginal atrophy.
You may also be interested in...
Almirall Aims To Disrupt Actinic Keratosis Space With Klisyri
Helped by its convenient five-day dosing, the shortest of any topical treatment for the precancerous skin disease, the Spanish company believes Klisyri, already launched in the US, will become a popular alternative to current options for actinic keratosis.
EMA Stands Firm On Estradiol Cream Safety Measure After Doubts Over Impartiality
After a 14-year-old legal dispute, the European Medicines Agency has now repeated its safety review of high-strength estradiol creams for treating vaginal atrophy and says it stands by its original recommendation to place a limit on how long patients should use these products.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.